Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPARC-1: Neoadjuvant Spartalizumab and Canakinumab in Localized Clear Cell RCC
NCT04028245Phase 1Completed
- Sponsor
- Columbia University
- Start
- Aug 2019
- Primary completion
- Mar 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of spartalizumab and canakinumab in renal cell carcinoma (RCC), sponsored by Columbia University. Primary endpoint: Percentage of subjects who proceed to radical nephrectomy at 6 weeks. Started Aug 2019; status: completed.
02
Drugs
spartalizumabcanakinumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04028245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04028245.